Chronic Granulomatous Disease Market Research Report – Forecast to 2027

Chronic Granulomatous Disease Market Research Report: By Diagnosis (Neutrophil Function Tests, Genetic Testing, Others), by Treatment (Infection Management, Interferon-gamma, Stem Cell Transplantation), by End-User (Hospitals, Others) - Forecast Till 2027

ID: MRFR/Pharma/4986-HCR | | Region: Global | 100 pages

Chronic Granulomatous Disease Market Scenario


The global chronic granulomatous disease market is expected to grow at a steady pace over the forecast period. The chronic granulomatous disease is a rare inherited disorder which is passed on from parents to their children. People with this disease have weak immune systems which leave their body vulnerable to chronic inflammation and frequent bacterial and fungal infections. The symptoms of this disease develop in the infancy or in the early childhood. The symptoms of this disease vary from person to person. Some common signs and symptoms may include frequent bacterial and fungal infections, swollen lymph nodes, persistent diarrhea, abscesses involving liver, lungs, spleen, bones, or skin.

Factors such as the growing prevalence of rare diseases, increasing expenditure on healthcare sector in the developed economies, and increasing research and development activities are anticipated to drive the growth of the market. However, expensive diagnostic tests and lack of awareness about the disease in the developing and underdeveloped economies may hinder the chronic granulomatous disease market growth over the forecast period. For instance, the cost of genetic testing ranges from USD 100 to USD 2,000.

Segmentation


The global chronic granulomatous disease market has been segmented into type, diagnosis, treatment, and end user.


The market, on the basis of type, is segmented into X-linked chronic granulomatous disease and autosomal recessive chronic granulomatous disease.


The market, by diagnosis, has been segmented into neutrophil function tests, genetic testing, prenatal testing, and others.


The market, by treatment, has been segmented into infection management, interferon-gamma, stem cell transplantation, and others. The infection management segment has been further segmented into trimethoprim, sulfamethoxazole, itraconazole, and others.


On the basis of end user, the market has been segmented into hospitals, clinical laboratories, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic granulomatous disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European chronic granulomatous disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The chronic granulomatous disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. This market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Pfizer, Inc., InterMune, Inc., Novartis AG, Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., and Horizon Pharma Plc are some prominent player in the market.


Regional Market Summary


Global Chronic Granulomatous Disease Market Share (%), by Region, 2017


Chronic Granulomatous Disease Market Share


Source: Centers for Disease Control and Prevention (CDC), Eurostat, National Center for Biotechnology Information (NCBI)


Geographically, the Americas is anticipated to dominate the global chronic granulomatous disease market owing to a well-developed healthcare sector, rising prevalence of rare diseases, steady growing occurrence of chronic granulomatous disease (CGD), and relatively large number of research and development activities. According to an article published by the National Center for Biotechnology Information (NCBI) in 2017, the incidence of CGD in the US is around 1 in 200,000 to 1 in 250,000 births.


Europe is expected to hold the second largest position in the chronic granulomatous disease market. The market growth in this region is attributed to the rising prevalence of rare diseases and increasing research and development activities. According to the Eurostat, the gross domestic expenditure (GERD) on R&D was EUR 303 billion in the year 2016.


The chronic granulomatous disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, rising prevalence of rare diseases, growing awareness about rare diseases, and increasing government funding for the healthcare sector.


On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector, and growing prevalence of CGD and growing government initiatives for the healthcare sector. As per to an article published in the National Center for Biotechnology Information (NCBI) in 2017, the incidence of CGD is 1 in 70,000 in the Israeli Arab population.


Global Chronic Granulomatous Disease Market, by Type



  • X-Linked Chronic Granulomatous Disease

  • Autosomal Recessive Chronic Granulomatous Disease


Global Chronic Granulomatous Disease Market, by Diagnosis



  • Neutrophil Function Tests

  • Genetic Testing



  • Prenatal Testing

  • Others


Global Chronic Granulomatous Disease Market, by Treatment



  • Infection Management

  • Trimethoprim

  • Sulfamethoxazole

  • Itraconazole

  • Others

  • Interferon-gamma

  • Stem cell transplantation

  • Others


Global Chronic Granulomatous Disease Market, by End-User



  • Hospitals

  • Clinical Laboratory

  • Others


Global Chronic Granulomatous Disease Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • The Middle East & Africa



  • Middle East

  • Africa


Intended Audience



  • Pharmaceutical & Biopharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Institutes

  • Academic Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2013-2018: 7.8%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer, Inc., InterMune, Inc., Novartis AG, Lonza Group, GlaxoSmithKline Plc, Eli Lilly and Company, Janssen Pharmaceuticals, Merck KGaA, Osiris Therapeutics, Inc, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., and Horizon Pharma Plc
  Key Market Opportunities   Growing awareness about rare diseases, and increasing government funding for the healthcare sector
  Key Market Drivers

  • Growing prevalence of rare diseases
  • Increasing expenditure on healthcare sector in the developed economies
  • Increasing research and development activities


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Chronic granulomatous disease market would be driven by increased expenditure for infrastructural setup and research activities, government initiatives, and others.

    The market growth would be hindered by the high cost of genetic testing.

    The segments are sulfamethoxazole, itraconazole, trimethoprim, and others.

    The diagnosis segment would include genetic testing, prenatal testing, neutrophil function tests, and others.

    The players are InterMune, Inc., Pfizer, Inc., Lonza Group, Novartis AG, Eli Lilly and Company, GlaxoSmithKline Plc, Merck KGaA, Janssen Pharmaceuticals, JCR Pharmaceuticals Co., Ltd., Maxcyte Inc., Osiris Therapeutics, Inc, and Horizon Pharma Plc.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Chronic Granulomatous Disease Market, by Type

    6.1 Introduction

    6.2 X-Linked Chronic Granulomatous Disease

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Autosomal Recessive Chronic Granulomatous Disease

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7. Global Chronic Granulomatous Disease Market, by Diagnosis

    7.1 Introduction

    7.2 Neutrophil Function Test

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.3 Genetic Testing

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.4 Prenatal Testing

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.5 Others

    Chapter 8. Global Chronic Granulomatous Disease Market, by Treatment

    8.1 Introduction

    8.2 Infection Management

    8.2.1 Trimethoprim

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.2.2 Sulfamethoxazole

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.2.3 Itraconazole

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.2.4 Others

    8.3 Interferon-gamma

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4 Stem Cell Transplantation

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.5 Others

    Chapter 9. Global Chronic Granulomatous Disease Market, by End-User

    9.1 Introduction

    9.2 Hospitals

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    9.3 Clinical Laboratory

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    9.4 Others

    Chapter 10. Global Chronic Granulomatous Disease Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12. Company Profiles

    12.1 Pfizer, Inc.

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 InterMune, Inc.

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Novartis AG

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Lonza Group

    12.4.1 Company Overview

    12.4.2 Product Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 GlaxoSmithKline Plc

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Eli Lily and Company

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Janssen Pharmaceuticals

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Merck KGaA

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Osiris Therapeutics, Inc.

    12.9.1 Overview

    12.9.2 Product Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 JCR Pharmaceuticals Co., Ltd

    12.10.1 Overview

    12.10.2 Product Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 Maxcyte, Inc.

    12.11.1 Overview

    12.11.2 Product Overview

    12.11.3 Financials

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.12 Horizon Pharma Plc

    12.12.1 Overview

    12.12.2 Product Overview

    12.12.3 Financials

    12.12.4 Key Developments

    12.12.5 SWOT Analysis

    12.13 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s Viewpoint

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Predictions for the Chronic Granulomatous Disease Industry

    Chapter 14. Appendix


    LIST OF TABLES

    Table 1 Global Chronic Granulomatous Disease Market Synopsis, 2020–2027

    Table 2 Global Chronic Granulomatous Disease Market Estimates and Forecast, 2020–2027

    (USD Million)

    Table 3 Global Chronic Granulomatous Disease Market, by Region, 2020–2027 (USD Million)

    Table 4 Global Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD Million)

    Table 5 Global Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD Million)

    Table 6 Global Chronic Granulomatous Disease Market, by Treatment, 2020–2027(USD Million)

    Table 7 Global Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD Million)

    Table 8 North America: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD

    Million)

    Table 9 North America: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD

    Million)

    Table 10 North America: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD

    Million)

    Table 11 North America: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD

    Million)

    Table 12 US: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD Million)

    Table 13 US: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD Million)

    Table 14 US: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD Million)

    Table 15 US: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD Million)

    Table 16 Canada: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD Million)

    Table 17 Canada: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD Million)

    Table 18 Canada: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD

    Million)

    Table 19 Canada: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD

    Million)

    Table 20 South America: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD

    Million)

    Table 21 South America: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD

    Million)

    Table 22 South America: Chronic Granulomatous Disease Market, by Treatment, 2020–2027

    (USD Million)

    Table 23 South America: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD

    Million)

    Table 24 Europe: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD Million)

    Table 25 Europe: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD Million)

    Table 26 Europe: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD

    Million)

    Table 27 Europe: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD Million)

    Table 28 Western Europe: Chronic Granulomatous Disease Market, by Type, 2020–2027

    (USD Million)

    Table 30 Western Europe: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027

    (USD Million)

    Table 31 Western Europe: Chronic Granulomatous Disease Market, by Treatment, 2020–2027

    (USD Million)

    Table 32 Western Europe: Chronic Granulomatous Disease Market, by End-User, 2020–2027

    (USD Million)

    Table 33 Eastern Europe: Chronic Granulomatous Disease Market, by Type, 2020–2027

    (USD Million)

    Table 34 Eastern Europe: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027

    (USD Million)

    Table 35 Eastern Europe: Chronic Granulomatous Disease Market, by Treatment, 2020–2027

    (USD Million)

    Table 36 Eastern Europe: Chronic Granulomatous Disease Market, by End-User, 2020–2027

    (USD Million)

    Table 37 Asia-Pacific: Chronic Granulomatous Disease Market, by Type, 2020–2027 (USD

    Million)

    Table 38 Asia-Pacific: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027 (USD

    Million)

    Table 39 Asia-Pacific: Chronic Granulomatous Disease Market, by Treatment, 2020–2027 (USD

    Million)

    Table 40 Asia-Pacific: Chronic Granulomatous Disease Market, by End-User, 2020–2027 (USD

    Million)

    Table 41 Middle East & Africa: Chronic Granulomatous Disease Market, by Type, 2020–2027

    (USD Million)

    Table 42 Middle East & Africa: Chronic Granulomatous Disease Market, by Diagnosis, 2020–2027

    (USD Million)

    Table 43 Middle East & Africa: Chronic Granulomatous Disease Market, by Treatment, 2020–2027

    (USD Million)

    Table 44 Middle East & Africa: Chronic Granulomatous Disease Market, by End-User, 2020–2027

    (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Chronic Granulomatous Disease Market

    Figure 3 Segmentation Market Dynamics for Global Chronic Granulomatous Disease Market

    Figure 4 Global Chronic Granulomatous Disease Market Share, by Type, 2020

    Figure 5 Global Chronic Granulomatous Disease Market Share, by Diagnosis, 2020

    Figure 6 Global Chronic Granulomatous Disease Market Share, by Treatment, 2020

    Figure 7 Global Chronic Granulomatous Disease Market Share, by End-User, 2020

    Figure 8 Global Chronic Granulomatous Disease Market Share, by Region, 2020

    Figure 9 North America: Chronic Granulomatous Disease Market Share, by Country, 2020

    Figure 10 Europe: Chronic Granulomatous Disease Market Share, by Country, 2020

    Figure 11 Asia-Pacific: Chronic Granulomatous Disease Market Share, by Country, 2020

    Figure 12 Middle East & Africa: Chronic Granulomatous Disease Market Share, by Country, 2020

    Figure 13 Global Chronic Granulomatous Disease Market: Company Share Analysis, 2020 (%)

    Figure 14 Pfizer, Inc.: Key Financials

    Figure 15 Pfizer, Inc.: Segmental Revenue

    Figure 16 Pfizer, Inc.: Geographical Revenue

    Figure 17 InterMune, Inc.: Key Financials

    Figure 18 InterMune, Inc.: Segmental Revenue

    Figure 19 InterMune, Inc.: Geographical Revenue

    Figure 20 Novartis AG: Key Financials

    Figure 21 Novartis AG: Segmental Revenue

    Figure 22 Novartis AG: Geographical Revenue

    Figure 23 Lonza Group : Key Financials

    Figure 24 Lonza Group: Segmental Revenue

    Figure 25 Lonza Group : Geographical Revenue

    Figure 26 GlaxoSmithKline Plc: Key Financials

    Figure 27 GlaxoSmithKline Plc: Segmental Revenue

    Figure 28 GlaxoSmithKline Plc. Geographical Revenue

    Figure 29 Eli Lily and Company: Key Financials

    Figure 30 Eli Lily and Company: Segmental Revenue

    Figure 31 Eli Lily and Company: Geographical Revenue

    Figure 32 Janssen Pharmaceuticals: Key Financials

    Figure 33 Janssen Pharmaceuticals: Segmental Revenue

    Figure 34 Janssen Pharmaceuticals: Geographical Revenue

    Figure 35 Merck KGaA: Key Financials

    Figure 36 Merck KGaA: Segmental Revenue

    Figure 37 Merck KGaA: Geographical Revenue

    Figure 38 Osiris Therapeutics, Inc.: Key Financials

    Figure 39 Osiris Therapeutics, Inc.: Segmental Revenue

    Figure 40 Osiris Therapeutics, Inc.: Geographical Revenue

    Figure 41 JCR Pharmaceuticals Co., Ltd: Key Financials

    Figure 42 JCR Pharmaceuticals Co., Ltd: Segmental Revenue

    Figure 43 JCR Pharmaceuticals Co., Ltd: Geographical Revenue

    Figure 44 Maxcyte, Inc.: Key Financials

    Figure 45 Maxcyte, Inc.: Segmental Revenue

    Figure 46 Maxcyte, Inc.: Geographical Revenue

    Figure 47 Horizon Pharma Plc: Key Financials

    Figure 48 Horizon Pharma Plc: Segmental Revenue

    Figure 49 Horizon Pharma Plc: Geographical Revenue